Baidu
map

PLoS Biol:大开绿灯的黑色素瘤加速癌症恶化

2014-10-21 佚名 生物谷

近日,来自格拉斯格大学的癌症研究人员通过研究发现,黑色素瘤细胞或许会“追随”机体一种天然产生分子的轨迹,而这种天然产生的分子则可以直接引起恶性皮肤癌发生扩散,相关研究刊登于国际杂志PLoS Biology上。 文章中,研究者发现黑色素瘤细胞或许可以通过一种名为溶血磷脂酸(LPA)的分子来给自己开绿灯从而进行扩散,LPA分子可以促进黑色素瘤细胞在机体中移动扩散。通过对癌症细胞系和小鼠进行研究,

近日,来自格拉斯格大学的癌症研究人员通过研究发现,黑色素瘤细胞或许会“追随”机体一种天然产生分子的轨迹,而这种天然产生的分子则可以直接引起恶性皮肤癌发生扩散,相关研究刊登于国际杂志PLoS Biology上。

文章中,研究者发现黑色素瘤细胞或许可以通过一种名为溶血磷脂酸(LPA)的分子来给自己开绿灯从而进行扩散,LPA分子可以促进黑色素瘤细胞在机体中移动扩散。通过对癌症细胞系和小鼠进行研究,研究者发现肿瘤细胞可以通过分解附近环境中的LPA分子来开启其在机体中的“旅行”。一旦周围环境中LPA分子的水平下降,肿瘤细胞就会离开肿瘤母体去寻找含有更高水平LPA的环境。

和其它癌症不同,黑色素瘤细胞从一开始就可以扩散,因此一旦LPA分子给予了黑色素瘤细胞扩散的方向,他们就会开始在机体扩散,这就意味着黑色素瘤很难对付,因为其扩散和恶化的速度很快。Robert Insall教授表示,令我们非常激动的是,皮肤癌细胞可以为自己开绿灯来引发癌细胞扩散,下一步我们的目的是去揭示黑色素瘤细胞如何破碎LPA分子来开启其癌症的扩散之旅的,目前研究者尚处于研究初期,他们希望可以通过更为深入的研究来帮助医生们制定合理的疗法来治疗黑色素瘤病人。

目前被诊断为黑色素瘤的患者数量是40年前的5倍,在英国每年大约有1.3万人被诊断为该疾病,而且每年大约有2200人因该病而丧生;开发有效的疗法来抑制黑色素瘤细胞扩散对于有效控制黑色素瘤并且治疗该病非常关键。我们可以用衣服及时遮住太阳光或者避免太阳光直射来有效保护皮肤免于晒伤,进而降低患黑色素瘤的风险。

原始出处

Muinonen-Martin AJ1, Susanto O2, Zhang Q3, Smethurst E3, Faller WJ2, Veltman DM2, Kalna G2, Lindsay C4, Bennett DC5, Sansom OJ2, Herd R6, Jones R4, Machesky LM2, Wakelam MJ3, Knecht DA7, Insall RH2.Melanoma Cells Break Down LPA to Establish Local Gradients That Drive Chemotactic Dispersal.PLoS Biol. 2014 Oct 14;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680254, encodeId=613f1680254cc, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Mar 19 04:06:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917086, encodeId=fecd191e0867f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 13 10:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766905, encodeId=34461e66905a1, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 23 16:06:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558670, encodeId=bc4a15586e0e9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564679, encodeId=aa0d15646e9b0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=)]
    2015-03-19 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680254, encodeId=613f1680254cc, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Mar 19 04:06:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917086, encodeId=fecd191e0867f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 13 10:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766905, encodeId=34461e66905a1, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 23 16:06:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558670, encodeId=bc4a15586e0e9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564679, encodeId=aa0d15646e9b0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=)]
    2015-01-13 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680254, encodeId=613f1680254cc, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Mar 19 04:06:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917086, encodeId=fecd191e0867f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 13 10:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766905, encodeId=34461e66905a1, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 23 16:06:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558670, encodeId=bc4a15586e0e9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564679, encodeId=aa0d15646e9b0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680254, encodeId=613f1680254cc, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Mar 19 04:06:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917086, encodeId=fecd191e0867f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 13 10:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766905, encodeId=34461e66905a1, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 23 16:06:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558670, encodeId=bc4a15586e0e9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564679, encodeId=aa0d15646e9b0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680254, encodeId=613f1680254cc, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Mar 19 04:06:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917086, encodeId=fecd191e0867f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 13 10:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766905, encodeId=34461e66905a1, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 23 16:06:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558670, encodeId=bc4a15586e0e9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564679, encodeId=aa0d15646e9b0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 23 00:06:00 CST 2014, time=2014-10-23, status=1, ipAttribution=)]

相关资讯

黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止(COMBI-v试验)

葛兰素史克(GSK)近日宣布,独立数据监测委员会(IDMC)已建议III期COMBI-v(MEK116513)提前终止。COMBI-v是一项III期研究,在BRAF V600E或V600K突变阳性不可切除性或转移性黑色素瘤患者中开展,调查了黑色素瘤药物Mekinist(trametinib)+Tafinlar(dabrafenib)组合疗法相对于vemurafenib的疗效。 IDMC

Cell Rep:不同肿瘤细胞可相互协作促进恶性黑色素瘤的扩散

近日,刊登在国际杂志Cell Reports上的一篇研究论文中,来自曼彻斯特大学的研究人员表示,皮肤癌细胞可以互相合作实现在机体中的快速扩散,某些黑色素瘤细胞生长速度尤其之快,但这些癌细胞却并不擅长于侵袭周围的组织,而其它黑色素瘤细胞则完全相反,它们虽然生长缓慢但是可以快速实现周围组织的侵袭,相关研究为开发新型药物来治疗黑色素瘤提供了一定帮助。在肿瘤组织中一种名为捎带细胞(Piggy-backin

CSMO 2014 :黑色素瘤新近进展

在7月4日的第八届中国肿瘤内科大会会上,郭军教授介绍了黑色素瘤的最新进展。 近几年黑色素瘤的治疗一直在创造一个又一个神话。3年前,CTLA单抗Ipi第一次证实了能够延长晚期黑色素瘤患者的总生存。2年前,BRAF抑制剂维莫非尼将晚期黑色素瘤的疗效由过去的7-8%,提高到53%,并大大延长PFS和OS。一年前,BRAF抑制剂联合MEK抑制剂将晚期黑色素瘤治疗有效率提高到75%左右,并进一步延长了PF

CSCO 2014:马建辉:更多关注,更多交流,更多成就

        中国医学科学院肿瘤医院、肾癌及泌尿肿瘤论坛策划负责人:马建辉教授 广纳贤士,不断成长 在早年的CSCO会场上,肾癌及泌尿肿瘤很少被肿瘤医生所关注,因为泌尿系统肿瘤中的肾癌、膀胱癌及前列腺癌等多属于化疗“抗拒”型肿瘤,且在肿瘤内科医生中真正关心泌尿系统肿瘤或者从事相关内科研究者其实并不多。所以泌尿

皮肤有痣?警惕患黑色素瘤风险!

黑色素瘤是皮肤癌中最常见的,但最严重的类型。根据墨尔本大学、牛津大学和Epworth HealthCare专家公布的一项研究证实:假如你皮肤有痣,患黑色素瘤的风险会翻两番。 研究人员比较两组人的医疗记录,其中一组271656人在因任何疾病而进行医院访问时被记录有痣,另一组10130417人没有痣记录。两组比较发现,相比没有记录痣的一组,有痣记录的一组更容易患黑素瘤,风险增加约4.

CSMO 2014 :口腔颌面-头颈黏膜黑色素瘤的个体化诊治与思考

在7月4日的第八届中国肿瘤内科大会会上,郭伟教授作了题为”口腔颌面-头颈黏膜黑色素瘤的个体化诊治与思考“的主题报告。  恶性黑色素瘤(malignant melanoma) 起源于上皮的黑色素细胞,是一类恶性程度极高的肿瘤,可发生于皮肤、口腔黏膜和视网膜等处。头颈部是恶性黑色素瘤的高发区,原发性头颈部皮肤黑色素瘤占全身黑色素瘤的25%左右,而头颈部黏膜恶性黑色素瘤占全身黏膜恶

Baidu
map
Baidu
map
Baidu
map